chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 29-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J006155 and expiry date 30-AUG-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought that the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would have been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different Lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX Lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to on an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his record didn't indicate when he received each Lot but he was calling further for the data. He also could not identify, at this time, which Lot # was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of the ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 20-MAY-2013, the patient was vaccinated with ZOSTAVAX (lot # H022152 and expiry date 18-MAR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought that the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would have been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different Lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX Lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to on an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his record didn't indicate when he received each Lot but he was calling further for the data. He also could not identify, at this time, which Lot # was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of the ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 20-MAY-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought that the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would have been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different Lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX Lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to on an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his record didn't indicate when he received each Lot but he was calling further for the data. He also could not identify, at this time, which Lot # was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of the ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 12-JUN-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might have been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to on an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which lot # was administered on which date. Pharmacist would call back after he had complied all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the dates of administration as well as the lot and expiration dates of ZOSTAVAX which was supported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 24-MAY-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 08-MAY-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 20-MAY-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 06-JUN-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 28-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J006155 and expiry date 30-AUG-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 24-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J000433 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 24-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 24-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J006155 and expiry date 30-AUG-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Age: 60.0
Sex: F
Vaccine: FLU3
Symptoms: Asthenia, Dysstasia, Headache, Hyperhidrosis, Nausea
Clinical narrative: 30 min. after shot - Rt. arm heavy, feeling weak. 45 min. after shot - diaphoretic, nauseated & weaker. 1 hr. after shot - too weak to stand.  Home to bed, headache & Rt. arm throbbing, Took Tylenol, slept. 5 hrs. after shot - symptoms gone. Has never happened before!
Age: 60.0
Sex: F
Vaccine: FLU3
Symptoms: Pain in extremity, Sensation of heaviness
Clinical narrative: 30 min. after shot - Rt. arm heavy, feeling weak. 45 min. after shot - diaphoretic, nauseated & weaker. 1 hr. after shot - too weak to stand.  Home to bed, headache & Rt. arm throbbing, Took Tylenol, slept. 5 hrs. after shot - symptoms gone. Has never happened before!
Age: 4.0
Sex: M
Vaccine: DTAPIPV
Symptoms: Injection site erythema, Irritability, Vaccination site rash, Vaccination site warmth
Clinical narrative: Hot and red rash at vaccination site, irritability.
Age: 21.0
Sex: M
Vaccine: HEPAB
Symptoms: Feeling of body temperature change, Immediate post-injection reaction
Clinical narrative: Pt reported feeling "hot & cold" immediately after receiving vacination; No headache, dizziness, nausea or difficulty breathing reported.
Age: 67.0
Sex: F
Vaccine: VARCEL
Symptoms: Rash
Clinical narrative: Rash noted on right side of back from beneath the bra line to slightly below the waist.
Age: 66.0
Sex: F
Vaccine: PPV
Symptoms: Blood test, Cellulitis, Erythema, Pain in extremity, Swelling
Clinical narrative: Soreness of Arm, Swelling, Redness.  No Fever.  Went to physician's office.  She was diagnosed with Cellulitis.
Age: 64.0
Sex: M
Vaccine: IPV, YF
Symptoms: Mobility decreased, Musculoskeletal pain, Nuclear magnetic resonance imaging
Clinical narrative: Severe shoulder pain and immobility.
Age: 4.0
Sex: M
Vaccine: FLUX, IPV, MMRV
Symptoms: Fatigue, Gait disturbance, Irritability, Pain in extremity, Vomiting
Clinical narrative: Vomiting; Leg pain (limping); Tiredness; Fussiness.
Age: 41.0
Sex: M
Vaccine: FLU4
Symptoms: Aphonia, Chills, Cough, Lymphadenopathy, Oropharyngeal pain
Clinical narrative: Woke up with very bad aches and chills, then developed swollen lymph nodes, heavy chest coughs, pain in adam's apple, loss of voice several times, infected saliva glands, sinus infection over several months. I still am suffering from issues and not completely back to full health and it is now February. I still am having some issues that won't go away.
Age: 41.0
Sex: M
Vaccine: FLU4
Symptoms: Pain, Sialoadenitis, Sinusitis
Clinical narrative: Woke up with very bad aches and chills, then developed swollen lymph nodes, heavy chest coughs, pain in adam's apple, loss of voice several times, infected saliva glands, sinus infection over several months. I still am suffering from issues and not completely back to full health and it is now February. I still am having some issues that won't go away.
Age: 0.71
Sex: F
Vaccine: FLUX
Symptoms: Febrile convulsion, Influenza A virus test positive, Pyrexia
Clinical narrative: seizure for 9 minutes. first and only febrile seizure.
Age: 66.0
Sex: M
Vaccine: FLU3
Symptoms: Discomfort, Hypoaesthesia, Injection site pain, Orthosis user, Pain in extremity
Clinical narrative: I experienced acute pain in my upper left arm where I had received my flu shot injection. The severe pain traveled down my arm to my thumb. My thumb has been numb at times and other times in severed pain as well. Eventually, after waiting until the discomfort to subside, I went to my Dr. and was given a thumb/wrist brace to wear. The pain/discomfort is still present today. After nearly 4 months I am not sure if the effects will subside. I am planning another trip to my Dr.
Age: 61.0
Sex: M
Vaccine: FLUX
Symptoms: Blister, Induration, Injection site induration, Injection site mass, Injection site pain
Clinical narrative: Just after receiving flu shot injection the site itched, stung and was tender with localized swelling. My wife is an RN and suggested ibuprofen and ice. The next morning it was fine. It was about 48 hours later I first noticed a rash. I only noticed it when showering because the area around the injection site felt oddly hard and lumpy. It did not itch and was not tender. Because I do not have any food or medicine allergies and had no other symptoms my wife gave me Benadryl and put some hydrocortisone cream on the rash. She described it as "small fluid filled vesicles, similar to shingles or a cluster of herpes-type blisters. As mentioned the skin and "rash" felt hard. The only thing my RN wife could come up with that may cause this reaction was the possibility of the preservative (Thimerosal) used in the multi-dose flu vaccine. When contacting the Pharmacy they denied using multi-dose vials and said they only use prefilled single dose syringes. The pharmacist told my wife they had been aware of the preservative being previously used in single-dose injections but we're not sure if the ones they used had the preservative or not. Two days later the rash has almost resolved. My wife did take a photo of the rash.
Age: 61.0
Sex: M
Vaccine: FLUX
Symptoms: Injection site pruritus, Injection site swelling, Rash, Rash vesicular
Clinical narrative: Just after receiving flu shot injection the site itched, stung and was tender with localized swelling. My wife is an RN and suggested ibuprofen and ice. The next morning it was fine. It was about 48 hours later I first noticed a rash. I only noticed it when showering because the area around the injection site felt oddly hard and lumpy. It did not itch and was not tender. Because I do not have any food or medicine allergies and had no other symptoms my wife gave me Benadryl and put some hydrocortisone cream on the rash. She described it as "small fluid filled vesicles, similar to shingles or a cluster of herpes-type blisters. As mentioned the skin and "rash" felt hard. The only thing my RN wife could come up with that may cause this reaction was the possibility of the preservative (Thimerosal) used in the multi-dose flu vaccine. When contacting the Pharmacy they denied using multi-dose vials and said they only use prefilled single dose syringes. The pharmacist told my wife they had been aware of the preservative being previously used in single-dose injections but we're not sure if the ones they used had the preservative or not. Two days later the rash has almost resolved. My wife did take a photo of the rash.
Age: 74.0
Sex: F
Vaccine: FLU3
Symptoms: Limb discomfort, Pain in extremity
Clinical narrative: No treatment. Pain/discomfort. Right arm. Soreness in injected arm; increasing with time (since October 23, 2013, or 10/30/13 increasing to today, Feb. 1 2014).
Age: 65.0
Sex: F
Vaccine: FLU3, VARZOS
Symptoms: Injection site erythema, Injection site swelling, Injection site warmth
Clinical narrative: 2 days after injection had approx. 2 inch across, red, raised, warm at injection site.
Age: 28.0
Sex: F
Vaccine: HEP
Symptoms: Anxiety, Dizziness, Feeling abnormal, Flushing, Tachycardia
Clinical narrative: Patient came back to pharmacy reporting tachycardial, dizziness, and flushing. Said she felt wrong. She sat down and after 20 minutes she said she was feeling better. She said that it gave her a feeling of anxiety.
Age: 7.0
Sex: M
Vaccine: FLUN4
Symptoms: Acoustic stimulation tests normal, Ear discomfort, Hyperacusis, Tinnitus
Clinical narrative: About 20 minutes after the shot patient first complained that his ears felt "weird".   Later he complained of distorted hearing.  Patient complained that his ears were hearing shouting when we were just talking, especially his right ear.  He had a hard time understanding what we were saying.  The next morning when we asked more questions and noticed it was still bothering him, he said it sounded like a constant ringing in his ears and when he heard sounds they didn't go away.  He complained again that it sounded like we were shouting when we weren't.  The school nurse checked his ears and although he could hear all the sounds, when the beep of the test stopped, he still thought it was going.  She recommended we take him back to the pediatrician where he got the live flu nasal mist vaccine the day before.  We went and they did a hearing test and said that since he could still hear, we shouldn't worry and that if the ringing was still happening on Monday to bring him back.  He still is having a hard time understanding what he is hearing from his right ear and is still hearing constant ringing in both ears.
Age: 1.06
Sex: M
Vaccine: FLU4, HIBV, MMR, PNC13, VARCEL
Symptoms: Febrile convulsion
Clinical narrative: Febrile seizure 24 hours after vaccination.
Age: 44.0
Sex: F
Vaccine: YF
Symptoms: Encephalitis, Intensive care
Clinical narrative: Meningitis encephalitis.
Age: 23.0
Sex: F
Vaccine: HPV4
Symptoms: Contusion, Injection site induration, Injection site mass, Pain in extremity, Syncope
Clinical narrative: Syncope, intense arm pain, bruising, small hard lump at injection site.
Age: 63.0
Sex: F
Vaccine: FLU3
Symptoms: Arthralgia, Back pain, Dysstasia, Gait disturbance, Joint injection
Clinical narrative: Severe lower back pain, joint pain and muscle pain- could not stand or walk w/o extreme pain for two- three weeks- could not put any weight on right hip and leg for four months at which time I had an injection of cortisone in hip joint at which time pain was localized to muscles in right leg that continue to be painful.
Age: 63.0
Sex: F
Vaccine: FLU3
Symptoms: Myalgia, Weight bearing difficulty, X-ray of pelvis and hip
Clinical narrative: Severe lower back pain, joint pain and muscle pain- could not stand or walk w/o extreme pain for two- three weeks- could not put any weight on right hip and leg for four months at which time I had an injection of cortisone in hip joint at which time pain was localized to muscles in right leg that continue to be painful.
Age: 0.6
Sex: M
Vaccine: DTAP
Symptoms: Chills, Crying, Lethargy, Pyrexia, Staring
Clinical narrative: High Fever x3 days 103-104 degrees.  Lethargic. Tremors. Blank Stares. Chills. Unconsolable crying.
Age: 0.6
Sex: M
Vaccine: DTAP
Symptoms: Tremor
Clinical narrative: High Fever x3 days 103-104 degrees.  Lethargic. Tremors. Blank Stares. Chills. Unconsolable crying.
Age: 39.0
Sex: F
Vaccine: FLUX
Symptoms: Mobility decreased, Musculoskeletal pain, Pain
Clinical narrative: Pain in shoulder, difficulty lifting arm, pain when lifting arm.
Age: 1.32
Sex: F
Vaccine: DTAP, MMR, VARCEL
Symptoms: Blister, Pyrexia, Rash, Rash erythematous, Rash papular
Clinical narrative: Developed fever x3 days with onset of rash on the 3rd day. Has erythematous papules that started on the forehead and spread downward. Few of the red bumps have clear fluid or white fluid.
Age: 37.0
Sex: M
Vaccine: FLUX
Symptoms: Computerised tomogram normal, VIIth nerve paralysis
Clinical narrative: On the afternoon of 10/19, the left side of my face began to feel like it wasn't functioning properly despite appearing to look normal.  By evening I was dropping food out of my mouth.  I went to the ER late that evening and was diagnosed with Bell's palsy.  The next morning I awoke to find the right side of my face was paralyzed and the left had pretty much returned to normal.  I haven't fully recovered 14 weeks later.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Viral infection
Clinical narrative: Standard symptoms and antiviral treatment.
Age: 80.0
Sex: F
Vaccine: TDAP
Symptoms: Erythema, Local swelling, Skin warm
Clinical narrative: About 2 weeks post injection, patient noticed large (approximately 4 in x 4 in) area on arm - red, warm to touch, slightly raised. Patient contacting PCP on Monday 1-3-14.
Sex: U
Vaccine: HEP
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to a multiple unspecified patients of unknown age and gender. On an unspecified date the multiple unspecified patients were administered a dose of RECOMBIVAX HB (lot # unspecified) (dose, route, frequency and location unspecified) that went through an unsupported temperature excursion. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: This spontaneous report as received from a pharmacist refers to a pediatric patient. The pharmacist reported that the patient received an adult dose of VAQTA (strength, dose, frequency and lot # not reported) on 29-JAN-2014. No adverse symptoms were reported. It was unspecified if the patient sought medical attention. Additional information has been requested.
Sex: U
Vaccine: HIBV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to a multiple unspecified patients of unknown age and gender. On an unspecified date the multiple unspecified patients were administered a dose of LIQUID PEDVAXHIB (lot # unspecified) (dose, route, frequency and location unspecified) that went through an unsupported temperature excursion. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to a multiple unspecified patients of unknown age and gender. On an unspecified date the multiple unspecified patients were administered a dose of PNEUMOVAX23 (lot# unspecified) (dose, route, frequency and location unspecified) that went through an unsupported temperature excursion. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Age: 62.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Injection site erythema, Injection site swelling, Injection site vesicles, Injection site warmth
Clinical narrative: Approximately 4 inch area of pink tissue at site of injection. Darker red area (approx. -> 2 inches) in the middle of pink skin. Warm, swollen at site of injection. Appears to be 2 small blisters within red area of skin.
Age: 62.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Injection site erythema, Injection site vesicles, Injection site warmth
Clinical narrative: Approximately 4 inch area of pink tissue at site of injection. Darker red area (approx. -> 2 inches) in the middle of pink skin. Warm, swollen at site of injection. Appears to be 2 small blisters within red area of skin.
Age: 78.0
Sex: F
Vaccine: PPV
Symptoms: Cellulitis, Injection site erythema, Injection site induration, Injection site pain, Injection site reaction
Clinical narrative: Pt describes "severe pain" and not being "able to lift arm" with onset about 2hrs after injection. Presently she presents with a local inj. site reaction including soreness, erythema, warmth, swelling, and induration. She may also have a cellulitis type reaction the skin is taught.
Age: 78.0
Sex: F
Vaccine: PPV
Symptoms: Injection site swelling, Injection site warmth, Mobility decreased, Skin tightness
Clinical narrative: Pt describes "severe pain" and not being "able to lift arm" with onset about 2hrs after injection. Presently she presents with a local inj. site reaction including soreness, erythema, warmth, swelling, and induration. She may also have a cellulitis type reaction the skin is taught.
Age: 60.0
Sex: F
Vaccine: FLU3, VARZOS
Symptoms: Dysphonia, Injection site erythema, Injection site pain, Injection site rash, Injection site warmth
Clinical narrative: 12/30/13 Rash, redness, soreness, at injection site 24 hrs after receiving shingles shot on left arm. Arm still sore after 1 month of shot. Hoarseness of voice also. 1/31/14 Rash, redness, warmth, soreness at injection site after pneumonia shot. Arm slightly sore from shingles.
Age: 60.0
Sex: F
Vaccine: FLU3, VARZOS
Symptoms: Pain in extremity
Clinical narrative: 12/30/13 Rash, redness, soreness, at injection site 24 hrs after receiving shingles shot on left arm. Arm still sore after 1 month of shot. Hoarseness of voice also. 1/31/14 Rash, redness, warmth, soreness at injection site after pneumonia shot. Arm slightly sore from shingles.